Denis Bedoret

EXO Biologics SA operates as a Belgian biotechnology company. The company is based in Liege, Belgium. The company was founded in 2019. Hugues Wallemacq has been the CEO of the company since 2021.

Uteron Pharma SA is engaged in the research and development of controlled release devices. The firms products Levosert and Diafert provide pharmaceutical solutions for women's health. The company was founded by Stijn van Rompay in 2010 and is headquartered in Grâce-Hollogne, Belgium.

Docpharma NV provides generic drugs. These drugs are used to treat infections, hypertension, allergies, bronchial and asthmatic problems, gastric and vomiting discomforts, pain and depression. It was founded by Leon Van Rompay in 1999 and is headquartered in Heverlee, Belgium.

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Vivaldi Biosciences Inc. develops and markets vaccines. It specializes in developing live attenuated influenza vaccines (LAIVs). The company was founded by Eliott Kieff, Peter Palese, and Adolfo García-Sastre in 2006 and is headquartered in Fort Collins, CO.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

KitoZyme SA manufactures biopolymers and provides medical device products. It develops and produces chitosan (and derivatives), chitin-glucan and beta-glucan, exclusively extracted from renewable, non-GMO vegetable sources. The firm specializes in weight management, digestive health and cardiovascular health products. The company was founded in December 2000 and is headquartered in Herstal, Belgium.

AXI NV provides software solutions. It offers managed and interim support, migration, database, infrastructure, disaster recovery, virus protection, and data communication services. The firm also engages in the design, implementation, management, and support of multi-vendor hardware and networks. The company was founded in 1970 and is headquartered in Willebroek, Belgium.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Part of Mencare Invest NV, Encare is a Belgian company that provides insurance services. The company is based in Hasselt, Belgium.

Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium.

Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre.

Univercells SA designs single-use cost-efficient bioprocess solutions to open the next chapter in bio manufacturing. The company was founded by Jose Castillo, Guillaume De Viron and Hugues Bultot in 2013 and is headquartered in Gosselies, Belgium.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium.

Ovizio Imaging Systems SA develops and markets imaging systems and sensors. Its microscopes include iLine F, iLine M, iLine S and QMod. The company was founded by Catherine Yourassowsky, Frank Dubois, Philip Mathuis and Serge Jooris in December 2009 and is headquartered in Brussels, Belgium.

DNAVision SA operates as a research and development company. The firm provides genomic services to the pharmaceutical, food and biotechnology industries. It offers Non-Executive Directortgen seqencing, bioinformatics, sanger sequence, expression profiling, DNA extraction and biobanking. The company was founded in May 2004 and is headquartered in Charleroi, Belgium.

Artelis is a technology company that provides disposable bio process solutions, from optimization to intensification: ' Process intensification: design, development and manufacturing of innovative high-cell-density technologies that enable to dramatically increase volumetric productivity while significantly reduce the manufacturing scales. ' Process optimization: process development services with a view to improve customer's process Artelis' team comprises 40 individuals all of whom are highly experienced in cell culture and well aware of biotechnology companies' needs.

Part of Ncardia SA, Cellistic is a subsidiary that specializes in the process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The Belgian company's focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development make it an ideal partner for innovative cell therapy developers to commercialize novel advanced therapies. The company was founded by Stefan Braam, and Gustavo Mahler has been the CEO of the company since 2023.

TheClubDeal Capital Advisors SA (Private Equity) is a private equity/venture capital division of TheClubDeal Capital Advisors SA founded in 2016 by Nicolas de Moreau and Jean-Marc Legrand. The firm headquartered in Brussels, Belgium.

YUST Group NV provides real estate services. The company is based in Antwerp, Belgium and has subsidiaries in Belgium. The Belgian company was founded in 2018. Stephane Verbeeck has been the CEO of the company since 2019.